Press releases

24 April, 202019 February, 2024

Regulatory

Publication of supplementary prospectus related to NeuroVive’s rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...

20 April, 2020

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Wednesday, 20 May 2020 at Medicon V ...

3 April, 202019 February, 2024

Regulatory

NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...

17 March, 2020

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...

19 February, 2020

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2019

Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...

19 February, 2020

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 3 pm on Tuesday 17 March 2020 at Medicon Village, Scheelevägen 2, ...

20 November, 2019

Regulatory

NeuroVive Pharmaceutical AB Interim Report January – September 2019

Continued progress in KL1333.

21 May, 2019

Regulatory

NeuroVive Pharmaceutical AB Interim Report January – March 2019

First subjects enrolled in the KL1333 study

25 April, 2019

Regulatory

Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 25 April 2019, NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today on 25 April 2019 held its Annual General Meeting (AGM). A summary of the resolutions follows.

25 March, 2019

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (publ)

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 25, 2019, at 4 pm at Medicon Village, Scheelev ...

17 January, 2019

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 January 2019, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. All resolutions were unani ...

11 December, 2018

Regulatory

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Lund, Sweden, 11 December 2018 – NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018: